REDUCE Trial: Perineural Dexamethasone on Scalp Nerve Blocks

NACompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

December 13, 2020

Primary Completion Date

January 2, 2023

Study Completion Date

January 2, 2023

Conditions
Postoperative PainCraniotomyDexamethasoneScalp Nerve Blocks
Interventions
DRUG

Bupivacaine

The control group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus normal saline 1 ml. The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.

DRUG

Dexamethasone combined with bupivacaine

The DEX4mg group will receive scalp nerve blocks with 0.5% bupivacaine with epinephrine at 1:200,000, plus 4 mg dexamethasone (1 ml). The anesthesiologist will perform scalp nerve blocks based on the group allocation 10 mins before the incision. Scalp nerve blocks will be performed according to the technique previously described by Pinosky et al.

Trial Locations (1)

100070

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER

NCT04648358 - REDUCE Trial: Perineural Dexamethasone on Scalp Nerve Blocks | Biotech Hunter | Biotech Hunter